Results 31 to 40 of about 78,778 (305)

THE FEATURES OF CONNEXINS EXPRESSION IN THE CELLS OF NEUROVASCLAR UNIT IN NORMAL CONDITIONS AND HYPOXIA IN VITRO

open access: yesБюллетень сибирской медицины, 2014
The aim of this research was to assess a role of connexin 43 (Cx43) and associated molecule CD38 in the regulation of cell-cell interactions in the neurovascular unit (NVU) in vitro in physiological conditions and in hypoxia.Materials and methods.
A. V. Morgun   +4 more
doaj   +1 more source

One Single Nucleotide Polymorphism of the TRPM2 Channel Gene Identified as a Risk Factor in Bipolar Disorder Associates with Autism Spectrum Disorder in a Japanese Population

open access: yesDiseases, 2020
The transient receptor potential melastatin 2 (TRPM2) is a non-specific cation channel, resulting in Ca2+ influx at warm temperatures from 34 °C to 47 °C, thus including the body temperature range in mammals.
Naila Al Mahmuda   +6 more
doaj   +1 more source

The Many Facets of CD38 in Lymphoma: From Tumor–Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy

open access: yesCells, 2020
The CD38 antigen is expressed in several hematological malignancies, and the anti-CD38 monoclonal antibodies Daratumumab and Isatuximab have an established role in the therapy of multiple myeloma.
Eleonora Calabretta   +1 more
doaj   +1 more source

The effect of sodium deoxyribonucleate with iron complex on the expression of surface markers of MT-4 cells infected with human immunodeficiency virus type 1 (HIV-1) (Retroviridae: Primate lentivirus group)

open access: yesВопросы вирусологии
Introduction. The persistence of immune dysfunction during therapy has serious consequences for the health of HIV-infected people. Therefore, an important direction is the search for drugs that can reduce the inflammatory potential of the immune system ...
Dmitry N. Nosik   +3 more
doaj   +1 more source

Anti-CD38-IFNα(att) retains strong on-target tumor cell activity with reduced off-target activity in vitro.

open access: yes, 2016
Two assays were used to evaluate the antigen specificity of anti-CD38 targeted IFNα’s. The graphs on the left show viability assays of treated ARP-1 MM cells three days after incubation with IFNα compounds.
James Berenson (3111285)   +15 more
core   +1 more source

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?

open access: yesCells, 2020
During a time span of just a few years, the CD38 antibody, daratumumab, has been established as one of the most important new drugs for the treatment of multiple myeloma, both in the relapsed/refractory setting and, more recently, as a first-line ...
Torben Plesner   +2 more
doaj   +1 more source

Antigen specificity index (ASI) of anti-CD38-IFNα and attenuated variants.

open access: yes, 2016
Antigen specificity index (ASI) of anti-CD38-IFNα and attenuated variants.
James Berenson (3111285)   +15 more
core   +1 more source

Clinical findings and immunophenotypic profile of plasma cell leukemia: a retrospective study in a comprehensive cancer center in Turkey

open access: yesMedicine Science, 2021
Plasma cell leukemia (PCL) is a rare (1-2 %) aggressive plasma cell dyscrasia (PCD) with a poor prognosis and characterized by the presence of more than 20% circulating plasma cells (PCs).
Nurgul Ozcan   +7 more
doaj   +1 more source

Targeting CD38 for acute leukemia

open access: yesFrontiers in Oncology, 2022
Acute leukemia (AL) is a hematological malignancy, and the prognosis of most AL patients hasn’t improved significantly, particularly for relapsed or refractory (R/R) AL. Therefore, new treatments for R/R adult acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are urgently necessary.
Xushu Zhong, Hongbing Ma
openaire   +3 more sources

Enhanced tumor regression and synergistic activity of anti-CD38-IFNα(att) compared to standard MM therapeutics.

open access: yes, 2016
(A) Tumor volumes from NCI-H929 tumor bearing SCID mice treated with 5mg/kg anti-CD38-IFNα(att), twice a week for 3 weeks or standard MM therapeutic agents including dexamethasone (10 mg/kg, daily for 28 days), lenalidomide (25 mg/kg, daily for 21 days),
James Berenson (3111285)   +15 more
core   +1 more source

Home - About - Disclaimer - Privacy